Ignite Creation Date:
2024-05-05 @ 5:02 PM
Last Modification Date:
2024-10-26 @ 9:27 AM
Study NCT ID:
NCT00378521
Status:
COMPLETED
Last Update Posted:
2007-05-30
First Post:
2006-09-18
Brief Title:
Dose Response Study of a Topical Gel for the Treatment of Raynauds Phenomenon
Sponsor:
MediQuest Therapeutics
Organization:
MediQuest Therapeutics
Study Overview
Official Title:
Phase II Dose Response Study of a Topical Gel Formulation of Nitroglycerin MQX-503 in the Treatment of Raynauds Phenomenon
Status:
COMPLETED
Status Verified Date:
2007-05
Last Known Status:
None
Delayed Posting:
No
If Stopped, Why?:
Not Stopped
Has Expanded Access:
No
If Expanded Access, NCT#:
N/A
Has Expanded Access, NCT# Status:
N/A
Acronym:
None
Brief Summary:
The Purpose of this study is to determine the response to two different strengths of a topical gel containing nitroglycerin in patients with Raynauds disease
Detailed Description:
The Purpose of this clinical study is to determine in a controlled fashion the response to two dosage strengths of a topical gel formulation of Nitroglycerin MQX-503 in the determination of changes in finger blood flow and skin temperature in the fingers of patients with moderate to severe primary Raynauds phenomenon and with Raynauds phenomenon secondary to autoimmune diseases such as scleroderma The dosage strength response in the treatment of the symptoms pain tingling numbness will also be monitored
Study Oversight
Has Oversight DMC:
None
Is a FDA Regulated Drug?:
None
Is a FDA Regulated Device?:
None
Is an Unapproved Device?:
None
Is a PPSD?:
None
Is a US Export?:
None
Is an FDA AA801 Violation?:
None